The State Street SPDR S&P Biotech ETF (XBI) has surged 58% over the past year, currently trading at $128, with the potential to reach its all-time high of $175 from 2021. Analysts from Goldman Sachs and Mizuho project a positive outlook for the biotech sector in 2026, citing anticipated Federal Reserve rate cuts, increased merger and acquisition activity, and advancements in AI that could hasten drug discovery. XBI, which equally weights 145 biotech stocks, has an $8 billion AUM and is one of the largest healthcare sector ETFs, benefiting from a stronger focus on smaller companies. Despite past volatility, experts see significant upside potential due to ongoing industry developments.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/sectors/healthcare/articles/biotech-etf-still-well-below-141741856.html
